History of magnetic resonance imaging of the breast
===================================================

Some of the first images of the body produced with magnetic resonance imaging (MRI) were of the breast \[[@B1]\]. However, by the mid-1980s most investigators had concluded that there was little clinical utility for MRI in detecting or diagnosing breast cancer. The application of contrast agents to breast imaging, first published by Heywang and colleagues \[[@B2]\], changed that thinking and revealed that breast cancers, in comparison with normal breast tissue, were enhanced significantly with standard gadolinium contrast agents. Heywang\'s reports were followed closely by those of Kaiser and Zeitler \[[@B3]\], who also found contrast-enhanced magnetic resonance images useful in breast cancer diagnosis but by using a very different technique. Whereas Heywang and colleagues acquired one pre-contrast and two post-contrast sequences of a single breast, permitting high spatial resolution with a three-dimensional gradient echo technique, Kaiser and Zeitler obtained one pre-contrast and multiple post-contrast images of both breasts, permitting high temporal resolution.

This work by Heywang and Kaiser in the 1980s established that contrast-enhanced MRI could distinguish benign from malignant breast tissue; additional reports, including those by Harms and Kuhl in the 1990s \[[@B4],[@B5]\], contributed to our understanding of the optimal methods of image acquisition. Two basic camps were established, one focusing on the rapid acquisition of images of both breasts after contrast injection (high temporal resolution of the \'dynamic\' school) and the other focusing on three-dimensional gradient echo imaging with thin slices through one breast (high spatial resolution of the \'static\' school). The dynamic school tended to use image subtraction to suppress the high signal from fat, whereas the static school tended to eliminate the fat signal by more time-consuming methods of suppression. The dynamic school, more popular in Europe, helped to develop methods to evaluate various enhancement profiles over time, and the static school, more popular in the USA, helped to develop methods to distinguish morphologic features of malignant and benign lesions \[[@B6]\]. By 2000, most agreed that both high temporal and high spatial resolution were important in gaining information about both the pharmacokinetics and morphology of breast lesions. Importantly, current technology permits acquisition protocols that provide both high spatial resolution (≤3 mm slices with ≤1 mm in-plane spatial resolution) and high temporal resolution (fat-suppressed *T*~1~acquisitions covering both breasts in ≤2 min).

Breast MRI acquisition techniques
=================================

There are numerous acceptable methods of image acquisition, and no single method has proven superior to another. However, there are guidelines considered by most experts to be reasonable minimum requirements for achieving acceptable image quality.

A dedicated breast surface coil should always be used. Both unilateral and bilateral coils are available. Bilateral imaging has obvious advantages of cost, time, and patient convenience. Most coils sold today are for bilateral imaging and most are open, allowing for access to the breast tissue for MRI-guided interventions. The vast majority of published studies of breast MRI have been conducted on 1.5 T magnets, but there are some reports from 1.0 T scanners.

In 2003, the 4th edition of the manual for the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS^®^) included a section dedicated to the performance and reporting of breast MRI \[[@B7]\]. The committee acknowledged that no single method of image acquisition had been proven superior to others, but that reporting of breast MRI should include field strength, pre-contrast and post-contrast sequences used, method of fat suppression, and postprocessing performed (subtractions, axial, sagittal, coronal reconstructions, and/or maximum intensity projections).

Breast MR image interpretation
==============================

The American College of Radiology BI-RADS MRI lexicon for breast imaging includes detailed language for describing morphology and kinetics of lesions. All suspicious enhancing areas should be described as a focus or foci, mass or non-mass-like enhancement. Foci are typically less than 5 mm in diameter, whereas masses have defined convex margins. All mass descriptions should include reporting of mass shape, margin and internal enhancement. Non-mass-like enhancement descriptions should include distribution, internal enhancement and symmetry. Associated findings (such as edema, adenopathy, cysts, and skin or chest wall involvement) should be reported and kinetic curve assessment of all lesions described. Kinetic curve assessment should include initial peak enhancement (slow, medium, or rapid) and delayed-phase (persistent, plateau, or washout) analyses.

Clinical applications of breast MRI
===================================

Numerous reports evaluating the potential role of breast MRI in defined patient populations have been published. These studies cover the spectrum of cancer detection, diagnosis, and response to treatment evaluation, and include women with a mammographic or palpable abnormality, axillary adenopathy but unknown primary, current cancer diagnosis, and women at high risk for breast cancer.

Further evaluation of mammographic or palpable abnormality
----------------------------------------------------------

Initially, clinical studies of breast MRI focused on the potential role of MRI in further evaluation of a mammographic or palpable lesion. It was proposed that MRI could reduce the number of unnecessary biopsies recommended from traditional work-ups of mammographic or palpable lesions. However, although MRI was shown to have very high sensitivity it was not 100% sensitive and it demonstrated only moderate specificity. In 2004 the International Breast MRI Consortium published the largest (*n*= 821) multicenter study so far of patients recommended for biopsy based on abnormal mammogram, ultrasound, or clinical breast exam \[[@B8]\]. This study demonstrated that although MRI had very high sensitivity, 12% of cancers identified by mammography or clinical breast exam were negative on MRI. The authors concluded that MRI should not be used to overrule a recommendation for biopsy. It was also interesting that the use of dynamic MRI in this patient population did not improve accuracy compared with high-spatial-resolution three-dimensional MRI alone.

Evaluation of extent of disease
-------------------------------

Although negative or benign MRI findings cannot replace a recommendation for biopsy based on traditional methods, MRI does seem to be important in the assessment of extent of disease in patients with a recent diagnosis of breast cancer. This application was pioneered by Harms and colleagues \[[@B9]\] and confirmed by multiple reports over the past 15 years including that by Bedrosian and colleagues \[[@B10]\], all demonstrating that MRI can identify otherwise occult multicentric and multifocal disease in women with breast cancer. Harms compared results from *in vivo*MR images with serially sectioned pathologic analyses in 30 mastectomy specimens. MRI detected additional disease in 37% of specimens. Several subsequent reports confirmed the findings of Harms and colleagues, including a report from the University of Pennsylvania \[[@B11]\] that MRI changed management of 23% of patients scheduled for breast conserving therapy. In the largest multisite study so far, the International Breast MRI Consortium reported on 426 women with a current cancer diagnosis. MRI identified additional disease at least 2 cm from the index malignant lesion in 18% of patients \[[@B12]\].

The advantage of MRI in determining the extent of disease has also been demonstrated in studies evaluating the contralateral breast. In a recent study of 239 women with a breast cancer diagnosis who underwent prophylactic contralateral mastectomy (no known disease in the contralateral breast), 4.6% of women had cancer identified by pathology \[[@B13]\]. Interestingly, seven clinical studies of women with a recent cancer diagnosis have found that, on average, 4% of women will have otherwise occult contralateral cancers identified by MRI at the time of the initial breast cancer diagnosis \[[@B14]\]. These data suggest that most contralateral cancers can be detected at the time of the initial breast cancer diagnosis (Fig. [1](#F1){ref-type="fig"}).

Malignant adenopathy, unknown primary
-------------------------------------

A small percentage (1 to 2%) of breast cancer patients present with axillary adenopathy, unknown primary. Current treatment recommendations for these patients is mastectomy. However, MRI will detect the occult cancer in 75 to 85% of patients, allowing many of these to have lumpectomy rather than mastectomy \[[@B15]\].

Evaluation of response to neoadjuvant chemotherapy
--------------------------------------------------

In the mid-1990s, Gilles and colleagues \[[@B16]\] reported that MRI was superior to mammography and clinical breast exam in evaluating response to neoadjuvant chemotherapy. Subsequent studies supported these findings but cautioned that the false negative rate of MRI is increased after chemotherapy and MRI cannot exclude microscopic disease \[[@B17],[@B18]\].

Screening women at high risk for breast cancer
----------------------------------------------

Although all women are at risk for developing breast cancer, there are subgroups of women who can be identified by genetic testing or by risk modeling who are at significantly increased risk for breast cancer. For example, women who are carriers of the *BRCA1*mutation have an approximately 85% lifetime risk of developing breast cancer. In addition, women at increased risk tend to develop breast cancer at a younger age when mammography is less sensitive, probably because of increased mammographic density and increased growth rates of tumors in women of younger age (Fig. [2](#F2){ref-type="fig"}).

Multiple studies published since 2000 demonstrate that screening MRI can detect otherwise occult breast cancers in women at high risk (Table [1](#T1){ref-type="table"}) \[[@B19]-[@B25]\]. The first study published on screening MRI in high-risk women was by Kuhl and colleagues \[[@B19]\], who screened 192 women with mammography, MRI, and ultrasound. In that study, MRI detected 6 cancers in 192 women (3%) that were occult on both mammography and ultrasound. The largest screening MRI study so far \[[@B24]\] reported on 1,909 women at increased risk in the Netherlands, with 51 women diagnosed with cancer. The sensitivities of clinical breast examination, mammography, and MRI were 17.9%, 33%, and 79.5%, respectively. The overall discriminating capacity of MRI was significantly better than mammography as assessed by receiver operator curves (area under the curve: 0.83 for MRI versus 0.69 for mammography).

Although in all studies so far MRI sensitivity has been uniformly high, the specificity and positive predictive value of biopsies vary widely. The rates of biopsies performed in women undergoing screening MRI have ranged from 2.9% to 16%, with positive predictive value of those biopsies ranging from 17% to 89%. It is interesting that MRI specificity seems to improve after the first round of screening. Warner and colleagues \[[@B20]\] reported recall rates decreasing during the first, second and third rounds of MRI screening from 17% to 10% to 7%.

MRI has not been studied in the general population as a screening tool, and the results from MRI screening of high-risk women may not apply to women at average risk. The high cost of MRI (about 10 times the cost of mammography) and its variable specificity currently prohibit its routine use for screening general populations.

Two specific populations of women are considered to have relative contraindications to contrast-enhanced MRI: pregnant and nursing women. Other than early animal studies showing adverse effects on embryo development, there is little information about the risks of contrast-enhanced imaging during pregnancy. Little is also known about the transfer and effects of this agent on nursing infants. Makers of the agent gadodiamide (Omniscan; Amersham Health) identify it as a Category C drug and recommend caution in its use in these two specific populations, noting that contrast-enhanced imaging should be conducted on pregnant women only when the benefits of the exam are considered to outweigh the risks to the fetus. For nursing mothers, the current recommendation is to wait 24 hours after injection before resuming nursing.

Conclusion
==========

The use of breast MRI is increasing rapidly as this exciting technology improves and as data continue to become available supporting the value of this tool in select patient populations. Breast MRI is highly sensitive, with an acceptable specificity compared with other imaging modalities. Although MRI clearly detects cancers occult to mammography, ultrasound, and clinical breast exam, the impact of MRI on breast cancer recurrence or mortality has not been studied. Analyses of cost-effectiveness of MRI in distinct patient populations need to be performed. There is significant work to be done to optimize the application and performance of breast MRI. Research to clarify optimal acquisition protocols is needed. Recent work in breast MRI in 3 T magnets is very exciting and holds promise for even higher spatial and temporal resolution by providing a better signal : noise ratio. MRI spectroscopy, reviewed in another article in this series \[[@B26]\], may improve the specificity of MRI and might possibly predict the response to therapy and/or evaluate the very early response to chemotherapy. Novel contrast agents are being developed that may provide more sensitive and more specific discrimination of benign from malignant lesions. These rapidly advancing areas of research hold great promise for continued improvements in the earlier and more accurate diagnosis of breast cancer.
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![MRI results in a woman 52 years old with recent diagnosis of right breast cancer. Left mammogram negative. Pre-contrast **(a)**and post-contrast **(b)**enhanced sagittal MR images reveal an 8 mm enhancing mass at 12 o\'clock in the left breast (arrowed). Core needle biopsy confirmed infiltrating ductal carcinoma. Final pathology from lumpectomy demonstrated an 8 mm infiltrating ductal carcinoma; sentinel lymph node negative.](bcr1309-1){#F1}

![MRI results in a 46 year old woman at high risk for breast cancer. Sagittal pre-contrast *T*~2~**(a)**, post-contrast *T*~1~**(b)**and magnified view **(c)**of 8 × 3 × 3 linear focus of enhancement in left breast at six o\'clock (arrowed). The lesion was negative on mammography and screening ultrasound. Pathology proved infiltrating ductal carcinoma.](bcr1309-2){#F2}
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Comparative sensitivity of screening methods in women at increased risk for breast cancer

  Study site and reference   Study design   Follow-up, months   Mean age, years (range)   Cancers detected/screened, (%)   Sensitivity (%)   Cancer yield from MRI alone (%) \[95% CI\]^a^   Biopsies recommended as a result of MRI, %   PPV of biopsies performed on basis of MRI, %                    
  -------------------------- -------------- ------------------- ------------------------- -------------------------------- ----------------- ----------------------------------------------- -------------------------------------------- ---------------------------------------------- ---------------- ----
  Germany \[19\]             P              12                  39 (18--65)               4.7 (9/192)                      33 (3/9)          100 (9/9)                                       33 (3/9)                                     6/192 (3.1) \[0.9--6.0\]                       14/192 (7.3)     64
  Canada \[20\]              P              36                  47 (26--65)               9.3 (22/236)                     36 (8/22)         77 (17/22)                                      33 (7/21)                                    7/236 (3.0)^d^\[1.7--7.1\]                     37/236 (15.7)    46
  Italy \[21\]               P              24                  46 (25--77)               7.6 (8/105)                      13 (1/8)          100 (8/8)                                       13 (1/8)                                     7/105 (6.7) \[2.7--13.3\]                      9/105 (8.6)      89
  Netherlands \[22\]         P              12                  42 (22--68)               2.8 (3/109)                      0                 100 (3/3)                                       \-                                           3/109 (2.8) \[0.6--7.8\]                       5/109 (4.6)      60
  United States \[23\]       R              None                50^b^(23--82)             3.8 (14/367)                     0^c^              100 (14/14)                                     \-                                           14/367 (3.8) \[2.1--6.3\]                      59/367 (15.8)    24
  Netherlands \[24\]         P              33                  40 (19--72)               2.4 (45/1,909)^e^                40 (18/45)        71 (32/45)                                      \-                                           22/1,909 (1.2) \[1.1--2.4\]                    56/1,909 (2.9)   57
  International \[25\]       P              None                45 (26--86)               1.1 (4/367)                      25(1/4)           100 (4/4)                                       \-                                           3/367 (0.8) \[0.2--2.4\]                       23/367 (6.3)     17

P, prospective; PPV, positive predictive value; R, retrospective. ^a^Exact binomial confidence intervals. ^b^Reported median. ^c^To be included in this study, subjects had to have a negative mammogram. ^d^One patient who had an MRI-only cancer in this study did not receive ultrasound. ^e^Comparable sensitivity reported on 45 of 51 cancers in this study.
